Open AccessVenous thromboembolism in patients with heart failure
Author(s) -
О. В. Аверков,
И. В. Шевченко,
Т. Ш. Мирилашвили,
Ж. Д. Кобалава
Publication year - 2011
Publication title -
kardiovaskulârnaâ terapiâ i profilaktika
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.158
H-Index - 16
eISSN - 2619-0125
pISSN - 1728-8800
DOI - 10.15829/1728-8800-2011-4-101-106
Subject(s) - medicine , rivaroxaban , antithrombotic , fondaparinux , apixaban , tolerability , heart failure , venous thromboembolism , clinical trial , intensive care medicine , cardiology , warfarin , adverse effect , atrial fibrillation , thrombosis
This review is focussed on the problem of venous thromboembolism in patients with heart failure (HF). The results of the major clinical trials of antithrombotic therapy in HF patients are presented. The authors discuss comparative effectiveness, safety, and tolerability of unfractionated heparins, low molecular weight heparins, and fondaparinux. The results of the two trials, MAGELLAN and ADOPT, are expected to clarify the clinical potential of such oral anticoagulants as rivaroxaban and apixaban (Factor Xa inhibitors). The problem of low rates e of preventive antithrombotic administration is emphasized.